The AAA rupture recognition is a time-critical primary care emergency — the classic triad (pulsatile abdominal mass + back/flank pain + hypotension) is present in only approximately 50% of cases. The other 50% present with: isolated severe back pain (misdiagnosed as musculoskeletal), isolated flank pain (misdiagnosed as renal colic — patients may have been given diclofenac and sent home with serious consequences since diclofenac in AAA rupture reduces platelet aggregation and worsens haemorrhage), or painless syncope with incidental pulsatile mass on examination. The critical rule: any male over 65 with known or suspected AAA who presents with sudden-onset back, flank, or abdominal pain must have an AAA rupture excluded as the first priority — before considering renal colic, muscular pain, or any benign diagnosis. Do not examine forcefully — a tense, tender pulsatile epigastric mass in an unwell patient is almost certainly a ruptured AAA until proved otherwise.

The clinical distinction between splenomegaly and a left renal mass is a classic examination station that requires attention to specific signs — the three most reliable bedside differentiators: (1) the spleen cannot be felt above (you cannot get fingers between it and the ribs), whereas a left kidney can be ballot-ted bimanually and the examiner's hand can be placed above it; (2) the spleen moves medially and inferiorly with inspiration (toward the right iliac fossa in progressive enlargement), whereas the kidney moves downward with inspiration; (3) the spleen is dull to percussion anteriorly (no bowel between it and the abdominal wall), whereas the kidney is resonant anteriorly (bowel lies anterior to kidney). Additional distinguishing features: the notched medial border of an enlarged spleen (Traube's space — the area of resonance in the left lower costal area) is obliterated by a massively enlarged spleen. When clinical differentiation is uncertain: USS is definitive.

The Virchow's node (Troisier's sign) is a physical examination finding that carries significant oncological importance — a palpable hard, non-tender node in the left supraclavicular fossa (above the clavicle, just lateral to the sternocleidomastoid muscle) indicates metastatic spread from an intra-abdominal malignancy via the thoracic duct. The thoracic duct (which drains abdominal and thoracic lymphatics) empties into the venous circulation at the left subclavian-jugular junction, and tumour emboli can deposit at this terminal lymph node. The classic association is gastric cancer, but Virchow's node metastases also occur from: pancreatic, ovarian, colorectal, testicular, oesophageal, hepatic, and uterine carcinomas. Any palpable left supraclavicular lymph node in an adult with an abdominal mass should prompt urgent 2WW cancer referral — primary lymphoma of this node is possible but much less common than metastatic disease from an abdominal primary.

The Risk of Malignancy Index (RMI) is the validated tool for risk-stratifying ovarian masses in primary care — it combines three components: (1) menopausal status (M: pre-menopausal = 1; post-menopausal = 3); (2) USS features (U: none of the below = 1; any of multilocular cyst, solid areas, bilateral lesions, ascites, intraabdominal metastases = 3); and (3) CA125 level (IU/mL). The formula: RMI = M × U × CA125. Interpretation: RMI <25 = low risk (approximately 3% malignancy); RMI 25-250 = moderate risk (approximately 20%); RMI >250 = high risk (approximately 75% malignancy) — urgent 2WW gynaecology-oncology referral. GPs with access to USS and CA125 can calculate RMI and use it to determine urgency of referral. Important: RMI is not validated for premenopausal women with straightforward functional cysts — USS alone is usually sufficient for these, and most functional cysts (follicular, corpus luteum) resolve within 2-3 menstrual cycles without treatment.

The abdominal mass in primary care carries a significant malignancy probability that justifies a systematic urgent approach — a study by Hamilton et al. (BMJ, 2005) estimated that approximately 50% of palpable abdominal masses presenting to UK primary care have a malignant cause. Unlike many symptoms (which have a broad differential including benign conditions), a new palpable abdominal mass in an adult over 40 must be considered malignant until proved otherwise, and the primary care response should be: (1) urgent USS within 2 weeks; (2) 2WW cancer referral if clinical or USS features are suspicious; (3) never reassure without investigation. The practice of prescribing laxatives for a 'probable constipation mass' without arranging USS is clinically risky — a sigmoid carcinoma can present as a palpable LIF mass, and a caecal carcinoma as a RIF mass, both of which may soften and partially resolve with laxative treatment, giving false reassurance.

The colonoscopy after appendix mass resolution is a safety-critical investigation that is often omitted — a caecal carcinoma can perforate and present exactly like appendix abscess (perforated caecal carcinoma forms a pericolic mass that is clinically and radiologically indistinguishable from a perforated appendix phlegmon in approximately 5-10% of cases, particularly in patients over 50). After the appendix abscess has resolved with conservative management, colonoscopy at 6-8 weeks is mandatory to: (1) confirm the appendix is the source and exclude an underlying caecal carcinoma; (2) assess the caecum and terminal ileum for alternative pathology. An interval appendicectomy alone without prior colonoscopy in a patient over 50 is insufficient — the colonoscopy must precede or accompany the surgical planning.

The investigation before the 2WW appointment approach is a quality improvement initiative adopted by many NHS trusts — rather than submitting a 2WW referral and waiting for the hospital to arrange investigations (CT, endoscopy, blood tests) after the initial specialist consultation, GPs who arrange CT and tumour markers at the time of 2WW submission allow the specialist to review results before or at the first appointment, compressing the diagnostic timeline significantly. For suspected colorectal cancer: a GP-requested CT abdomen + pelvis often allows the cancer MDT to recommend straight-to-treatment colonoscopy or CT colonography directly, without an additional 2-week wait for staging imaging. The NHS Long-Term Plan (2019) and NHS Cancer Strategy both recommend that GPs should be empowered to request staging CT directly for suspected cancer, rather than deferring all investigation to the secondary care team.

The ERAS (Enhanced Recovery After Surgery) protocol for colorectal cancer surgery represents one of the most evidence-based peri-operative care innovations — it is a multi-modal package that reduces post-operative complications and hospital length of stay by 30-40%. Key ERAS elements relevant to GPs: (1) Pre-operative carbohydrate loading — patients drink a high-carbohydrate oral supplement (Preload or equivalent) the night before and 2 hours before surgery; this reduces post-operative insulin resistance, reduces muscle catabolism, and significantly shortens recovery. GPs may be asked to prescribe this; (2) Early mobilisation post-surgery — patients are encouraged to sit in a chair on day 0-1 post-operatively; (3) Minimal opioid post-operative analgesia — ERAS protocols use regional analgesia, NSAIDs, and paracetamol to minimise opioid use (opioids delay return of bowel function). GPs should support early discharge from hospital under ERAS protocols and be aware that patients may be discharged on day 2-3 post major colorectal resection — early discharge does not mean inadequate recovery.

The GP responsibility for tracking 2WW referral outcomes is a clinical governance standard that is frequently under-documented — NHS England and NICE guidance specifies that GPs who refer patients under the 2WW pathway retain a duty of care during the referral period. This includes: (1) having a system to track that the patient received an appointment (many GP practices use recall/task systems at day 10 to confirm appointment received); (2) having a system to receive and act on the specialist outcome letter (confirm receipt in the clinical record); (3) informing patients what the outcome was and what the follow-up plan is. A patient referred under 2WW who fails to attend their appointment ('did not attend') requires active follow-up from the GP — a simple letter or phone call, not passively waiting. The medicolegal principle: a GP who refers on 2WW and then has no further knowledge of whether the patient was seen and what was found is not fulfilling the minimum duty of care.